Evidence map›Paper›PMID 12632200›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2003

[(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.

J G Rajendran, D C Wilson, E U Conrad, L M Peterson, J D Bruckner, J S Rasey, L K Chin, P D Hofstrand, J R Grierson, J F Eary and 1 more

Registry-linked trialAbstract readClinical TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01886105 (Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma), which is not on this map. Cited by 93 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 3 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01886105 phase2terminatednot on this mapstarted 2013, after this paper: background citation

Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma

TypeinterventionalSponsorSidney Kimmel Comprehensive Cancer Center at Johns HopkinsRan2013 to 2017Enrolled4ConditionsMetastatic OsteosarcomaArmsSm-EDTMP, Autologous Stem Cell Infusion, External Beam Radiotherapy
3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 3 syntheses or guidelines pooled it, 248 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Radionuclide imaging of perfusion and hypoxia.European journal of nuclear medicine and molecular imaging · 2010
    Pooled it
  4. Prospective exploratory pilot study of 18 F-FMISO PET/CT for assessing tumor hypoxia in soft tissue sarcomas.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Trial
  5. Trial
  6. Pharmacokinetic Analysis of DynamicJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Multimodal Imaging of Hypoxia, Metabolism and pH in Feline Sarcoma Using HyperpolarizedAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  12. Review
  13. Review
  14. Development ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  15. Review
  16. Review
  17. Article
  18. Functionalized Ultrasmall Iron Oxide Nanoparticles forMolecules (Basel, Switzerland) · 2022
    Article
  19. Article
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

J G RajendranDepartment of Radiology, University of Washington Medical Center, Seattle, Washington 98195, USA, rajan@u.washington.edu
D C Wilson
E U Conrad
L M Peterson
J D Bruckner
J S Rasey
L K Chin
P D Hofstrand
J R Grierson
J F Eary
K A Krohn
University of Washington Medical Center · USBC Cancer Agency · CA

Funding

RadiochemistryP01CA042045 · NCI · UNIVERSITY OF WASHINGTON · PI SPENCE, ALEXANDER M · 1986 to 2015
$23.2M
PET IN SARCOMA--A CLINICAL TRIALR01CA065537 · NCI · UNIVERSITY OF WASHINGTON · PI EARY, JANET F. · 1995 to 2011
$5.0M
NUCLEAR IMAGING OF TUMORS:BIOLOGICAL AND CHEMICAL BASISR01CA034570 · NCI · UNIVERSITY OF WASHINGTON · PI KROHN, KENNETH A. · 1985 to 2001
$653k
NUCLEAR IMAGING OF TUMORS: BIOLOGICAL AND CHEMICAL BASISR37CA034570 · NCI · UNIVERSITY OF WASHINGTON · PI RASEY, JANET S · 1990 to 1997
–
NCI NIH HHS CA-34570NCI NIH HHS CA-42045NCI NIH HHS CA-65537NCI NIH HHS P01 CA042045NCI NIH HHS R01 CA065537
6 · The paper itself

Abstract

Hypoxia imparts resistance to radiotherapy and chemotherapy and also promotes a variety of changes in tumor biology through inducible promoters. The purpose of this study was to evaluate the use of positron emission tomography (PET) imaging with fluorine-18 fluoromisonidazole (FMISO) in soft tissue sarcomas (STS) as a measure of hypoxia and to compare the results with those obtained using [(18)F]fluorodeoxyglucose (FDG) and other known biologic correlates. FDG evaluates energy metabolism in tumors while FMISO uptake is proportional to tissue hypoxia. FMISO uptake was compared with FDG uptake. Vascular endothelial growth factor (VEGF) expression was also compared with FMISO uptake. Nineteen patients with STS underwent PET scanning with quantitative determination of FMISO and FDG uptake prior to therapy (neo-adjuvant chemotherapy or surgery alone). Ten patients receiving neo-adjuvant chemotherapy were also imaged after chemotherapy but prior to surgical resection. Standardized uptake value (SUV) was used to describe FDG uptake; regional tissue to blood ratio (>or=1.2 was considered significant) was used for FMISO uptake. Significant hypoxia was found in 76% of tumors imaged prior to therapy. No correlation was identified between pretherapy hypoxic volume (HV) and tumor grade ( r=0.15) or tumor volume ( r=0.03). The correlation of HV with VEGF expression was 0.39. Individual tumors showed marked heterogeneity in regional VEGF expression. The mean pixel-by-pixel correlation between FMISO and FDG uptake was 0.49 (range 0.09-0.79) pretreatment and 0.32 (range -0.46-0.72) after treatment. Most tumors showed evidence of reduced uptake of both FMISO and FDG following chemotherapy. FMISO PET demonstrates areas of significant and heterogeneous hypoxia in soft tissue sarcomas. The significant discrepancy between FDG and FMISO uptake seen in this study indicates that regional hypoxia and glucose metabolism do not always correlate. Similarly, we did not find any relationship between the hypoxic volume and the tumor volume or VEGF expression. Identification of hypoxia and development of a more complete biologic profile of STS will serve to guide more rational, individualized cancer treatment approaches.

Indexed as

Cell HypoxiaAdultAgedFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedMisonidazoleNeoplasm StagingRadiopharmaceuticalsSoft Tissue NeoplasmsTomography, Emission-ComputedVascular Endothelial Growth Factor AFluorodeoxyglucose F18fluoromisonidazoleMisonidazoleRadiopharmaceuticalsVascular Endothelial Growth Factor A

Identifiers

PMID12632200
OpenAlexW2074869766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.